Neurologic Drugs : Antiepileptics
OTEGR2 “Tegretol CR tablet” 200 mg/tab
適應症：癲癇症、三叉神經痛、腎原性尿崩症、雙極性疾患、原發性舌咽神經痛。
Usual dose:
Antiepileptic:
Adult ( >12 yrs): initial, 100-200 mg qd or bid with meals; maintenance, 800-1200 mg/day in 2-4 divided doses, max. 1.2 g/day in over 15 yrs and 1 g/day in 12-15 yrs.
Pediatric
(6-12 yrs): initial, 100 mg bid, may increase dosage by 100 mg/day at weekly intervals as needed, doses > 200 mg/day should be given in 3-4 divided doses, do not exceed 1000 mg/day.
(< 6 yrs): 10-20 mg/kg/day in 2-3 divided doses, max. 35 mg/kg/day.
Trigeminal neuralgia:
Adult: initial, 100 mg q12h, may increase by 200 mg/day (divided into 2 doses) as needed for pain control, max. 1200 mg/day.
Contraindication: bone marrow depression.
Adverse effect:
Common: hypertension, hypotension, lightheadedness, nausea, vomiting, clumsiness, confusion, dizziness, nystagmus, somnolence, blurred vision, diplopia.
Serious: atrioventricular block, cardiac dysrhythmia, congestive heart failure, syncope, stevens-johnson syndrome, toxic epidermal necrolysis, hypocalcemia, hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, acute intermittent porphyria, agranulocytosis, aplastic anemia, bone marrow depression, drug-induced eosinophilia, leukocytosis, leukopenia, pancytopenia, thrombocytopenia, hepatitis, systemic lupus erythematosus, aggravation, acute renal failure, nephrotoxicity, angioedema.
健保給付規範：（100/8/1）
1.使用於新病人：
（1）處方使用carbamazepine成分藥品之前，應先檢查病人IC健保卡是否已註記曾檢測帶有HLA-B 1502基因，檢測結果為陽性者，不得開立本藥。
（2）醫師欲為病人處方carbamazepine成分藥品前，應先詢問病人是否對該藥品有過敏病史，若為不確認者或未檢測者，宜先行作HLA-B 1502基因檢測。
2.使用於舊病人：若病人已服用4個月以上，且確認未曾出現喉嚨痛、嘴巴破或皮膚症狀（如分散的斑點或斑丘疹症狀）等類似Steven-Johnson症候群或其他不良反應時，可依病情繼續處方治療，但需提醒病人注意上述症狀之發生。
3.醫師為病人處方使用carbamazepine成分藥品，以日劑藥費申報者，應依規定詳實申報處方明細。